Elegen sets a new benchmark for clonal, cell-free synthetic DNA with ENFINIA, delivering unmatched length and accuracy from ...

Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct . The study, which was conducted by ...

When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a leader in next-generation cell-free DNA manufacturing, today announced a 25% reduction in price for ENFINIA™ DNA, making industry-leading long, complex, ...

Donor-derived cell-free DNA can aid detection, diagnosis, and monitoring of antibody-mediated rejection after kidney transplantation. Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker ...

Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj ...

Continued innovation of proprietary cell-free cloning technology has improved synthesis success rates, enabling pricing as low as $0.15 per base pair. SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a ...